During the routine use of a discrete analyser it was noted that, when the serum bilirubin concentration was greater than 50 J.Lmol/L, there was interference with serum phosphate determination measured by the formation of unreduced phosphomolybdate using a bichromatic system of measurement. The degree of interference was assessed by comparison with a reduced phosphomolybdate method (molybdenum blue). The interference cannot be removed by changing the secondary wavelength or by the use of a sample blank. It is proportional to the serum bilirubin concentration, but is not significant when this is less than 50 J.Lmol/L. The monochromatic non-reduced phosphomolybdate method compares well with the reduced method.
The routine measurement of serum and plasma phosphate has been carried out, for many years, by the formation of a phosphomolybdate complex which is reduced and measured colorimetrically. A number of reducing agents have been used,"? which yield a colloidal solution of molybdenum blue that is stable, specific and sensitive for application to blood plasma measurement. Adaptations of this method are almost universally applied in routine use, although other methods are cited using metavanadate to produce a non-reduced phosphovanadate complex," and malachite green to produce a dye complex.' The non-reduced phosphomolybdate complex shows a spectral shift proportional to the quantity of phosphate present, but because of poor sensitivity and high blank values, the method has not been applied to biological materials to any great extent. However, methods have been reported using extraction procedures' and centrifugal analysis' to overcome these problems. Modern discrete analysers have highly sensitive spectrophotometers which allow this method to be used without an increase in imprecision, and at the same time reducing the number of steps in the reaction.
In our laboratory a non-reduced phosphomolybdate method has been used with a bichromatic measurement to compensate for the non-specific chromogens in the sample. It was noted that specimens with an elevated serum bilirubin concentration tended to have low Correspondence: Dr G 0 Duncanson. phosphate concentrations. Further investigation has demonstrated that elevated levels of bilirubin interfere with this method of phosphate determination resulting in falsely low values, or 'pseudohypophosphataemia'.
MATERIALS AND METHODS

Samples
Serum samples (n = 55) sent to the laboratory for either liver function testing or bone profiling were selected to give a wide range of bilirubin concentration J.Lmol/L). Phosphate determination was carried out on each sample using the following methods. For the non-reduced method at 340 nm, analysis was only carried out on 25 samples as there was insufficient material.
Phosphate analysis
Non-reduced at 340/380nm Dichromatic measurement of non-reduced phosphomolybdate at 340 and 380 nm, the former being the primary wavelength coinciding approximately with the maximum absorption of phosphomolybdate. Phosphomolybdate is formed by the reaction of ammonium heptamolybdate, final concentration 2·7 mmol/L in sulphuric acid (800 mmol/L). Measurements were made using an ERIS Selective Multitest Analyser (DOH Ltd, Poole, UK).
Non-reduced at 340/380nm with blank Method as above, but including a serum blank which is subtracted from the sample value.
Duncanson and Worth
Non-reduced at 340/520nm Identical procedure to non-reduced method at 340/380 but using 520 nm as the secondary wavelength.
Analyser (American Monitor (UK) Ltd, Burgess Hill, UK). Phosphomolybdate is reduced using hydroxylamine sulphate (290 mmol/L) in sodium hydroxide (1,6 mol/L), Non-reduced at 340 nm Monochromatic measurement of non-reduced phosphomolybdate at 340 nm using an RA-500 analyser (Technicon Instruments Co Ltd, Basingstoke, UK). This uses a final ammonium molybdate concentration of 0·25 mmol/L in sulphuric acid (130mmol/L).
Bilirubin analysis
Bilirubin was measured by azo dye formation with 2,5-dichlorophenyldiazonium salt (I mmol/ L) in hydrochloric acid (0,04 mrnol/L) using the ERIS analyser. This is a bichromatic measurement, primary wavelength being 540 nm and the secondary 600 nm.
Reduced at 760 nm Monochromatic measurement of reduced phosphomolybdate at 760 nm using the Parallel
Bilirubin spectral analysis
The spectra of a jaundiced and a non-jaundiced serum were measured from 300-600 nm using a 
RESULTS
Phosphate was assayed on 55 serum samples having a wide range of bilirubin concentration. Analysis was carried out using the reduced molybdenum blue method and four different conditions of measurement for the non-reduced phosphomolybdate method. In the absence of a reference method, all data have been compared to results obtained with the reduced phosphomolybdate method, this being the method used by most laboratories. Figure 1 shows each of the non-reduced methods correlated with the reduced method using Demings correction." The datum points in Fig. 1 are denoted according to their bilirubin concentration. Three ranges of bilirubin concentration are used, 0-50 Jimol/L, 51-100 Jimol/L and greater than 100Jimol/L. By using the reduced method for reference, the deviation of each of the non-reduced methods was determined for samples where the bilirubin concentration was greater than 50 Jimol/L. The deviation of the phosphate value for each sample by each non-reduced method from the reduced method was determined by expressing the differ-ence between the two values as a percentage of the reduced method value. This percentage deviation was then plotted, for each of the nonreduced methods, against the bilirubin concentration and the correlation and regression equation determined using the method of least squares. These results are shown in Fig. 2 .
DISCUSSION
The advantage of using a reduced phosphomolybdate method for the measurement of phosphate is in the increased sensitivity that is achieved by the reduction. Modem analysers with highly sensitive spectrophotometers have rendered this unnecessary and consequently the non-reduced method is being used more frequently. A bichromatic determination is often used in an attempt to compensate for other chromogens in serum that absorb at 340 nm. The need for this is illustrated in Fig. 3 where the spectrum for a non-jaundiced serum (a) shows an absorbance due to non-specific chromogens at 340 nm. In the recommended method for the ERIS Selective Multitest Analyser this is compensated for at 380 nm. However, in Fig. 3, ( . . shows that this gives only partial compensation and the situation is very different when dealing with jaundiced sera where it can be seen that the spectra for a jaundiced serum (b) and a blanked jaundiced serum (c) have a higher absorbance at 380 nm than at 340 nm. Consequently a bichromatic measurement made at this secondary wavelength will overcompensate resulting in a falsely low phosphate measurement. It has been suggested that 520 nm is a more suitable secondary wavelength as it forms as isosbestic point for jaundiced and non-jaundiced sera. However, in both cases the absorbance is very different and lower than that at 340 nm suggesting an under compensation, resulting in falsely high phosphate measurement. Alternative approaches to the problem are to include a serum blank and to continue using 380 nm as the secondary wavelength or to use only a monochromatic measurement at 340 nm. The former is an unsatisfactory solution as the use of bichromatic measurement should obviate the need for a sample blank. By comparing these modifications to a reduced method a number of facts emerge. There appears to be a 'cut off' point at a bilirubin concentration of about 50 Ilmol/L below which the effect is not significant compared to the method imprecision. When the bilirubin concentration is between 50 and 100 Ilmoi/L the differences are probably not clinically significant (Fig. I ). As the bilirubin concentration increases the bichromatic methods show a deviation from the reduced method which relates with the bilirubin concentration, in each case the correlation coefficient is greater than 0·9. As predicted, the use of 380 nm as the secondary wavelength causes a significant reduction in the measured phosphate value which is partially compensated for by the inclusion of a sample blank, but values are still significantly falsely low. Also as predicted, the use of 520 nm as the secondary wavelength under compensates, giving falsely high values. Reference to the spectra in Fig. 3 will show that it is not possible to find a single secondary wavelength where the absorbance of non-specific chromogens and bilirubin is the same as their absorbance at 340 nm. It is not possible, therefore, to compensate fully for non-specific chromogens at any wavelength.
When the deviation of each method from the reducing method is compared in samples containing more than 50 Ilmoi/L bilirubin, the monochromatic measurement shows the least deviation. This gives acceptable results at the concentrations of bilirubin tested. All of these observations are illustrated in Fig. 2 . The deviation will be dependent on the phosphate con-centration as well as that of bilirubin. For this reason it is expressed as a percentage rather than the actual value, thus removing the effect of the sample to sample variation due to differing phosphate concentrations.
When the results of each bichromatic method are compared to the reduced method in samples with a bilirubin concentration greater than 50Ilmol/L they do not correlate well (Fig. 1) . Unblanked measurements have a correlation coefficient of less than 0.80. This is not surprising as the deviation is related to bilirubin concentration. Therefore, it is not possible (nor is it desirable) to include a factor to compensate for the bilirubin concentration. CONCLUSIONS 1. Bilirubin interferes with the determination of serum phosphate using a bichromatic system to measure non-reduced phosphomolybdate as the end point. 2. The degree and type of interference may be changed by altering the secondary wavelength or by including a sample blank, but it is not removed. 3. The interference is proportional to the bilirubin concentration, but is not significant when this is less than 50 Ilmol/L. 4. The degree of interference is sufficient to produce clinically misleading values for serum phosphate concentration in jaundiced patients, resulting in a pseudohypophosphataemia. 5. Monochromatic estimation of non-reduced phosphomolybdate does not show significant interference from bilirubin. 6 . If bichromatic measurement is to be used with jaundiced samples, clinicians must be made aware of the possibility of pseudohypophosphataemia. 7. In our laboratory we have selected 100 Ilmoi/L as the concentration of bilirubin above which interference is regarded as clinically significant.
